PNAS:卵巢癌早期诊断治疗新标记

2015-05-28 佚名 生物谷

众所周知,卵巢恶性肿瘤是女性生殖器官常见的恶性肿瘤之一,发病率仅次于子宫颈癌和子宫体癌而列居第三位。但卵巢上皮癌死亡率却占各类妇科肿瘤的首位,对妇女生命造成严重威胁。由于卵巢的胚胎发育、组织解剖及内分泌功能较复杂,早期症状不典型,卵巢癌的术前诊断相当困难。 最近,来自美国加州大学圣地亚哥分校的研究人员进行了一项研究,他们发现卵巢癌细胞能够编码6个mRNA亚型,这些mRNA在正常细胞中并不存在

众所周知,卵巢恶性肿瘤是女性生殖器官常见的恶性肿瘤之一,发病率仅次于子宫颈癌和子宫体癌而列居第三位。但卵巢上皮癌死亡率却占各类妇科肿瘤的首位,对妇女生命造成严重威胁。由于卵巢的胚胎发育、组织解剖及内分泌功能较复杂,早期症状不典型,卵巢癌的术前诊断相当困难。

最近,来自美国加州大学圣地亚哥分校的研究人员进行了一项研究,他们发现卵巢癌细胞能够编码6个mRNA亚型,这些mRNA在正常细胞中并不存在,这为卵巢癌的早期诊断和治疗提供了新的契机。这项研究结果即将发表在国际学术期刊PNAS上。
 
研究人员指出,DNA携带了生命所必需的各种指令,但DNA不仅包括能够编码蛋白质的基因,还有许多非编码的DNA序列,与此相比,mRNA只是蛋白编码基因的互补序列,它们携带了编码细胞内每个蛋白质的"秘诀"。一个癌细胞可能具有一个或几个DNA突变拷贝,但其编码的mRNA可以达到几百上千个拷贝,因此,相比于DNA,利用mRNA进行癌症诊断具有绝对数量的优势。
 
在该项研究中,研究人员利用生物信息学方法,对NIH的两个公共数据库的DNA和RNA序列进行了分析,将296名卵巢癌病人组织和1839名正常人卵巢组织进行对比之后发现了6个在卵巢癌细胞中特异性表达的mRNA亚型。随后他们又用实时定量PCR的方法在卵巢癌细胞系中进行了这些mRNA的鉴定,证实了他们的生物信息学分析结果。除此之外,研究人员指出,其中一些mRNA不仅具有诊断标记功能,其编码的蛋白质还可用于卵巢癌的靶向治疗。
 
综上所述,研究人员从卵巢癌病人组织中发现6个特异性表达的mRNA亚型,对于卵巢癌早期诊断和治疗具有重要意义。

原始出处:


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=49556, encodeId=e5c04955686, content=认真的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855733, encodeId=35771855e332f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Aug 13 22:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25590, encodeId=04692559026, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:19:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382623, encodeId=aae8138262329, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423620, encodeId=30921423620cc, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=)]
    2015-12-27 忠诚向上

    认真的知识

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=49556, encodeId=e5c04955686, content=认真的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855733, encodeId=35771855e332f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Aug 13 22:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25590, encodeId=04692559026, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:19:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382623, encodeId=aae8138262329, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423620, encodeId=30921423620cc, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=)]
    2015-08-13 drwjr
  3. [GetPortalCommentsPageByObjectIdResponse(id=49556, encodeId=e5c04955686, content=认真的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855733, encodeId=35771855e332f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Aug 13 22:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25590, encodeId=04692559026, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:19:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382623, encodeId=aae8138262329, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423620, encodeId=30921423620cc, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=)]
    2015-05-31 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=49556, encodeId=e5c04955686, content=认真的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855733, encodeId=35771855e332f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Aug 13 22:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25590, encodeId=04692559026, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:19:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382623, encodeId=aae8138262329, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423620, encodeId=30921423620cc, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=49556, encodeId=e5c04955686, content=认真的知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Dec 27 19:53:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1855733, encodeId=35771855e332f, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Thu Aug 13 22:09:00 CST 2015, time=2015-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25590, encodeId=04692559026, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Sun May 31 21:19:00 CST 2015, time=2015-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382623, encodeId=aae8138262329, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1423620, encodeId=30921423620cc, content=<a href='/topic/show?id=9ece91631bd' target=_blank style='color:#2F92EE;'>#诊断治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91631, encryptionId=9ece91631bd, topicName=诊断治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5afb3820115, createdName=feifers, createdTime=Sat May 30 00:09:00 CST 2015, time=2015-05-30, status=1, ipAttribution=)]

相关资讯

ONF:理解卵巢癌女性的痛苦

目的:当您在已确立诊断的治疗期间,您希望你们的配偶或对你们而言很重要的伴侣、家人、朋友和医务人员如何理解您的痛苦体验?若被问及这个问题,女性卵巢癌患者当时的心态如何?该实验的目的即在探究女性卵巢癌患者内心的痛苦想法,促使医务工作者更好地与患者沟通与交流。方式:我们依据修正后的格拉泽基础理论,并且与患者沟通访谈时采用音频录制的方式,因为以这种方式得到的数据进行分析所得结论相对恒定有意义。地点:该实验

Oncol Nurs Forum:罹患卵巢癌的女性对自身痛苦的认知

目的/目标: 通过询问“患有卵巢癌女性希望自己的伴侣,家人,朋友,和卫生保健提供者知道什么是他们在诊断和治疗的痛苦经历?”
,探索女性经历的痛苦。研究方法: 修正的Glaserian基础理论。设置: 一个在美国大西洋沿岸中部地区设定的项目。
参与者: 12名年龄在21 -71岁间诊断为卵巢癌以及进行治疗的女性
。方法学的方法: 对音频记录采访的数据进行常数的比较分析。
发现: 尽管个人经历不同,抽

Anticancer Res:卵巢癌的替代疗法---低剂量加压腹腔内气溶胶化疗 (PIPAC)

背景:八旬卵巢癌病人局限于腹部可能不愿意或者不能接受全身化疗。低剂量加压腹腔内气溶胶化疗 (PIPAC)与顺铂和阿霉素一起进行腹腔内化疗,可以反复应用,并可能防止系统性化疗产生的副作用。 病例报告:我们分析一个84岁的妇女腹腔镜和组织学证实卵巢癌情况下拒绝接受全身化疗的病例。她接受八个疗程的28 - 104天的低剂量PIPAC与顺铂7.5毫克/米(2)和阿霉素1.5毫克/米(2) 在大气压12毫

JAMA:别一刀切!不同BRCA突变致乳腺癌和卵巢癌风险不同

2013年5月,美国著名影星安吉丽娜.茱莉在《纽约时报》撰文,说她由于携带BRCA1基因突变而预防性切除了双侧乳腺,近期又有消息称她将切除双侧输卵管以预防卵巢癌。BRCA是抑癌基因,在调节细胞复制、DNA损伤修复、细胞正常生长方面有重要作用;如果BRCA基因突变,就丧失了抑制肿瘤发生的功能。BRCA突变类型达数百种之多,与人体的很多癌症的发生都有关系,其中关系最密切者是乳腺癌,其次是卵巢癌。然而,

AACR 2015:新方法更早检测卵巢癌

成功的治疗卵巢癌常常依赖于早期的确诊。德州大学MD安德森癌症中心的一项研究建立了一种新方法,可能帮助有此风险的女性们。"大多数尝试用血清生物标记物来检测早期卵巢癌的方法,都聚焦于检测CA125,"转化研究副主席Robert Bast Jr.医生说,"由于仅仅80%的卵巢癌表达CA125,多种生物标记物对于那些不表达这个抗原的患者就十分必要。"在先前的研究中,没有发现任何生物标记物会先于CA125而

Lancet Oncol:帕唑帕尼加每周紫杉醇用于晚期卵巢癌的II期临床研究

背景:血管生成抑制用于卵巢癌治疗是一种有价值的治疗策略。帕唑帕尼对卵巢癌具有抗血管生成活性。我们评估针对于耐药或铂类难治的晚期卵巢癌患者,紫杉醇治疗时增加帕唑帕尼对疗效的影响。方法:这是在意大利11家医院进行的,开放标签的、随机的II阶段临床试验。患者包括铂类耐药或铂类难治的晚期卵巢癌先前接受大于二线化疗的患者,东部合作肿瘤组性能状态0 - 1,无残留的外周神经毒性。病人随机分配接受每周紫杉醇(1